Bausch Health Companies Inc. (NYSE: BHC): Q4 2019 Earnings Snapshot

— Bausch Health Companies Inc. (NYSE: BHC) reported a loss of $4.30 per share for the fourth quarter of 2019, compared to a loss of $0.98 per share last year, vs. $1.15 per share loss expected.

— Net loss for the quarter was $1.516 billion, compared to a loss of $344 million a year earlier

— December-quarter revenues increased 5% annually to $2.22 billion, vs. $2.2 billion expected

— Revenue of Bausch + Lomb/International, the main business segment, grew 3% annually; Salix segment revenue was up 21%

— Received FDA approval for ARAZLO Lotion for the topical treatment of acne vulgaris in young adults

— Raised capital allocation for research and development by 14% in fiscal 2019, compared to last year

— Expects full-year 2020 revenues to be in the range of $8.65 billion to $8.85 billion

— Looking for adjusted EBITDA in the range of $3.50 billion to $3.65 billion for fiscal 2020

Listen to publicly listed companies’ earnings conference calls along with the edited closed caption text